Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Drops By 62.7%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 15,500 shares, a decrease of 62.7% from the January 31st total of 41,500 shares. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily volume of 143,200 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Stock Up 3.2 %

SNOA stock traded up $0.07 during midday trading on Friday, reaching $2.27. The stock had a trading volume of 25,438 shares, compared to its average volume of 43,747. Sonoma Pharmaceuticals has a twelve month low of $2.15 and a twelve month high of $9.37. The firm has a market cap of $3.67 million, a price-to-earnings ratio of -0.56 and a beta of 1.43. The business has a fifty day simple moving average of $2.61 and a two-hundred day simple moving average of $2.62.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Wednesday, February 5th. The company reported ($0.59) EPS for the quarter. Sonoma Pharmaceuticals had a negative net margin of 26.82% and a negative return on equity of 68.98%. On average, equities analysts predict that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.